Latest News about DSKYF
Recent news which mentions DSKYF
From Benzinga
From Benzinga
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
January 28, 2025
From Benzinga
From Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
December 06, 2024
From Benzinga
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
From Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
From Benzinga
Double Good News For AstraZeneca's Breast Cancer Drugs
April 29, 2024
From Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
From Benzinga
What's Going On With Pfizer Stock Today?
January 25, 2024
From Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
From Benzinga
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
From Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
From Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
From Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
From Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
From Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
From Benzinga
From Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
From Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
From Benzinga
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
August 15, 2022
From Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
From Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
From Benzinga